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Abstract
Background: Distal motor neuropathies with a genetic origin have a heteroge-
neous clinical presentation with overlapping features affecting distal nerves and
including spinal muscular atrophies and amyotrophic lateral sclerosis. This
indicates that their genetic background is heterogeneous. Patient and methods:
In this work, we have identified and characterized the genetic and molecular
base of a patient with a distal sensorimotor neuropathy of unknown origin. For
this study, we performed whole-exome sequencing, molecular modelling, clon-
ing and expression of mutant gene, and biochemical and cell biology analysis of
the mutant protein. Results: A novel homozygous recessive mutation in the
human VRK1 gene, coding for a chromatin kinase, causing a substitution
(c.637T > C; p.Tyr213His) in exon 8, was detected in a patient presenting since
childhood a progressive distal sensorimotor neuropathy and spinal muscular
atrophy syndrome, with normal intellectual development. Molecular modelling
predicted this mutant VRK1 has altered the kinase activation loop by disrupting
its interaction with the C-terminal regulatory region. The p.Y213H mutant pro-
tein has a reduced kinase activity with different substrates, including histones
H3 and H2AX, proteins involved in DNA damage responses, such as p53 and
53BP1, and coilin, the scaffold for Cajal bodies. The mutant VRK1(Y213H)
protein is unable to rescue the formation of Cajal bodies assembled on coilin,
in the absence of wild-type VRK1. Conclusion: The VRK1(Y213H) mutant pro-
tein alters the activation loop, impairs the kinase activity of VRK1 causing a
functional insufficiency that impairs the formation of Cajal bodies assembled
on coilin, a protein that regulates SMN1 and Cajal body formation.
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Introduction
Hereditary neuropathies are characterized by involvement
of motor, sensory, and/or autonomic nerve fibers,1 and
are divided into three main categories: hereditary motor
and sensory neuropathies (HMSN), also known as Char-
cot–Marie-Tooth (CMT) disease, hereditary motor neu-
ropathy, and hereditary sensory and autonomic
neuropathy (HSAN).2 Distal neuropathies and spinal
muscular atrophy (SMA) are progressive diseases affecting
the lower motor neurons and characterized for a progres-
sive muscle loss and weakness, and have overlapping
symptoms.3 The most common forms of these diseases
are associated with deletions or mutations in CMT genes,
or in the exon of the SMN1 gene that is not compensated
by SMN23,4 and is involved in RNA processing mediated
by snRNP.5 However, there is heterogeneity in disease
presentation, evolution and manifestations, which has led
to the identification of novel genes implicated in the
pathogenesis of these diseases.3 These include alterations
in mechanisms that regulate RNA splicing and processing,
or in the subcellular structures where these functions take
place, such as Cajal bodies.
Cajal bodies (CBs) are assembled on coilin.6,7 CBs
organization and assembly are lost by either SMN1 deple-
tion,8 or VRK1 depletion,7 and both form part of a com-
mon complex.6,7 Coilin also forms complexes with
splicing snRNP.9–11 Moreover, both SMN112 and VRK113
bind to chromatin. Coilin levels and its posttranslational
modifications also affect RNA processing and splicing.14
In this context, VRK1 phosphorylates coilin in Ser184
and regulates its stability and assembly by protecting it
from ubiquitin-mediated proteasomal degradation in the
cytosol, facilitating its nuclear accumulation,7 and also
interacts with Heterogeneous nuclear ribonucleoprotein
A1 (hnRNP A1) and regulates telomerase activity and
telomere maintenance.15 CBs alterations can be alternative
pathogenic routes leading to distal neuromotor syn-
dromes, and in which multiple genes have been impli-
cated.16
Several very rare recessive mutations in the human
VRK1 gene, either homozygous or compound heterozy-
gous, have been detected in diseases affecting the motor
neuron, which have a phenotypic heterogeneity in their
clinical presentation.17–24 These VRK1 mutations are
recessive, and all of them are very rare, some hereditary,
and others de novo. Among the distal motor neuropathy
phenotypes associated with human VRK1 mutations are
SMA,17,20,23–25 ALS,19,20 and pontocerebellar hypoplasia.17
In this work, we have identified a novel homozygous
recessive mutation in the human VRK1 gene, and the
mutant protein has altered the folding of its activation
loop that prevents the activation of the kinase activity
leading to a deficiency in the assembly of Cajal bodies.
Patient, Materials, and Methods
Clinical characteristics of the patient
The patient, son of consanguineous parents and currently
35 years, presented initial symptoms at 4 years with a
progressive distal muscle weakness in legs and arms that
became much more severe with time. The child has a foot
deformity with pes cavus and bilateral foot drop, leading
to unstable walk with distal amyotrophy of lower and
upper members. Electromyogram, performed at 9 years,
detected a significant slowdown of motor and sensory
nerve conductance velocity. At 16 years required foot sur-
gical correction to allow for adequate standing. The dis-
ease progressed with time needing walking stick, and
currently is wheel chair bound. At 24 years there was a
significant loss of muscle strength, unable to raise from
sedestation without help, and at 34 years the patient can-
not use hands for feeding or writing. Normal intellectual
development and normal speech.
The parents are consanguineous first cousins, and the
father has epilepsy. Both parents have pes cavus.
Whole-exome sequencing
For whole-exome sequencing (WES), DNA was extracted
from peripheral blood of the patient using the Maxwell
16 system. DNA quality was determined measuring opti-
cal density with a DeNovix DS-11. Human exome was
enriched using the MedExome SeqCap EZ assay (Roche-
Nimblegen, CA), and sequenced using a NextSeq 500
(Illumina, CA) equipment. An average 71x coverage
depth was achieved along the target regions (exons
and  75 intronic nucleotides lanking the exon–intron
boundaries). Variants were identified by alignment
of reads against the Human reference genome sequence
(hg19), using BWA-0.7–12, GATK-3.5 procedures for the
detection of single nucleotide variants and indels and
exome depth for deletions and duplications. Annotation
of the variants was performed using Annovar
(2016Feb01) and filtering and prioritization was per-
formed using public (1000 genomes, Genome Aggregation
Database and Exome Variant Server) databases in order
to identify candidate variants related to the clinical
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phenotype. Variants were classified following the Ameri-
can College of Medical Genetics and Genomics (ACMG)
guidelines,26,27 Polyphen-228 and VarElect29 algorithms
were used to predict the effect of the variants. Sanger
sequencing in the index case, parents, and siblings was
performed to confirm the variant and to determine its
inheritance pattern.
Ethical compliance
The genomic study was performed for diagnosis in a case
of unknown origin and was approved by the Institutional
review board. Informed consent was obtained from each
subject.
Molecular modeling of structure
The 3D structure of the human Vaccinia-Related Kinase 1
(VRK1) wild-type protein was obtained from the Protein
Data Bank (PDB id: 2LAV).30 The dynamic molecular
modeling methods are described in Data S1.
Cloning of altered VRK1 gene, plasmids, and
mutagenesis
Human VRK1 was expressed from mammalian expression
vector, pCEFL-HA-VRK1,31 and bacterial expression
pGEX-4T-VRK1.31–34 The Y213H mutation was intro-
duced in these plasmids with the GeneArt Site-Directed
Mutagenesis System (Invitrogen-ThermoFisher). The pri-
mers for human VRK1-p.Y213H were: forward (50-
AGGAGTTCATAAAGAACACAAAGAAGACCCCAAAA-
30), and reverse (50-TTTTGGGGTCTTCTTTGTGT
TCTTTATGAACTCCT-30). VRK1 wild-type and the
p.Y213H variant proteins were expressed in E.coli from
constructs made in plasmid pGEX4T-GST-VRK1 for bac-
terial expression,32 or in pCEFL-HA-VRK1 for expression
in mammalian cells.34 The human Y213H mutation was
introduced in murine VRK1 (mVRK1) and cloned in
pCEFL-Myc-mVRK1 to generate pCEFL-Myc-mVRK1
(Y213H) plasmid. The primers used for murine VRK1-
Y213H forward (50- TGGAGTTCATAAAGAGCACAAG-
GAAGATCCCAAA-30) and reverse (50- TTTGGGA
TCTTCCTTGTACTCTTTATGAACTCCA-3. Full methods
are in Data S1.
Kinase assays
Kinase assays were performed as previously
described.31,34,35 Briefly, in vitro kinase assays with [32-
P]-cATP were performed with GST-VRK1 wild-type, or
the p.Y213H variant.7,31,36 Kinase assays with the follow-
ing substrates were previously published: histone H3,13,33
H2AX,13 p53,37,38 53BP1,39 and coilin.7 Full methods are
in Data S1.
Cell lines, transfections, and protein
analysis
All molecular and cellular methods have been reported
before and are detailed in cellular and in Data S1.34 Anti-
bodies are in Table S1.
Results
Genetic findings
Whole-exome sequencing detected in the patient a
homozygous mutation (NM_003384:exon8:c.T637C:
p.Y213H) in exon 8 of the VRK1 gene. This mutation
was detected in heterozygosis in both consanguineous
parents, and the two siblings of the patient (Fig. 1).
Heterozygous carriers have no neurological pathology.
Molecular modeling of VRK1(Y213H) variant
protein and functional prediction
Polyphen-2 analysis of this aminoacid substitution predicts
the highest damaging score. VarElect analysis predicts a
very high likelihood of causing a neuropathy and muscular
atrophy.29 To study the effect of the VRK1(Y213H) mutant
protein, the 3D structure of human VRK1 protein (2LAV)
was obtained from the Protein Data Bank.30 This structure
includes the position of the protein C-terminal tail, as well
as the structure of the VRK1 activation loop, where the
Tyr213 residue is located (Fig. S1). Tyr213 forms a T-
shaped stacking complex with Tyr311, located in an alpha
helix close to the activation loop (Fig. S1). This type of
Tyr-Tyr interactions has been shown as contributing to
structural protein stability,40 as is the case of the VRK1
activation loop. The mutant residue VRK1(Y213H) is
located in the activation loop of the kinase.30 To detect the
structural consequences of the Y213H mutant, models for
wild-type (VRK1-WT), and Y213H mutant (VRK1-Y213H)
proteins were subjected to 200 nsec of free molecular
dynamic (MD) simulation. The activation loop of the
VRK1-WT structure did not experience noticeable varia-
tions during the molecular dynamics trajectory, remaining
virtually unchanged after 200 nsec of MD (Fig. 2A). The
only variation suffered by the activation loop was the stabi-
lization of the C-terminal end of the protein, through the
formation of saline bridges between the negative amino
acid Glu361 and the positive residues Lys211 and Arg219
of the loop (Fig. 2A). This interaction remained stable for
more than 40% of the total simulation time. After 200 ns
of molecular dynamics (MD), the 3D structure of the
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VRK1(Y213H) mutant activation loop displayed a different
arrangement (Fig. 2B). His213 continued to interact with
Tyr311 but in the form of a parallel-displaced stacking,
which confers a completely different shape to the activation
loop. Because of this, the position of Lys211 suffered a
large displacement. The behavior of the VRK1(Y213H)
mutant differs of the VRK1-WT structure during the MD
trajectory. The mutant does not have a close interaction
between the specific residues of the activation loop and the
residues located in the regulatory C-terminal tail of the
protein, which are required for kinase activation,30,41 and
this structural change predicts a loss of kinase activity.
The VRK1(Y213H) variant kinase is
functionally deficient
To determine the functional effect of the VRK1(Y213H)
mutant, we performed in vitro kinase assays using several
of the known VRK1 substrates. These included histones
H3 and H2AX associated with chromatin remodeling,13
T   C   A   T   A   A   A   G   A   A  T/C A   C   A   A   A   G   A   A   G   A
Father
T   C   A   T   A   A   A   G   A   A  T/C A   C   A   A   A   G   A   A   G   A
T   C   A   T   A   A   A   G   A   A  T/C A   C    A   A   A   G   A    A   G   A
T   C   A   T   A   A   A   G   A   A  T/C A   C   A   A   A   G    A   A   G   A






Figure 1. Identification of a novel mutation in the human VRK1 gene coding for a nucleosomal kinase. Detection and confirmation of the VRK1
mutation in the five members of the family.
ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association 811
A. T. Marcos et al. Homozygous VRK1 (Y213H) Mutant in Distal Motor Neuropathy
coilin required for Cajal body formation,7 p53,42 and
53BP1 39 involved in different aspects of DNA damage
responses.43 The mutant VRK1(Y213H) was compared
with the wild-type VRK1. In the kinase assays, the effect
of the p.Y213H mutant was common to all substrates.
There was a significant loss regarding the phosphorylation
of histone H3, (Fig. 3A), histone H2AX (Fig. 3B), coilin
(Fig. 3C), p53 (Fig. 3D), and 53BP1(Fig. 3E).
Protein stability of the VRK1(Y213H) mutant
Several of the known VRK1 mutants associated with neu-
rological phenotypes also have a reduced protein stabil-
ity.34 Therefore, we tested the stability of p.Y213H
compared to the normal VRK1 protein. Plasmids express-
ing both proteins were transfected in 293T cells, which
were treated with cycloheximide, and the level of protein
was determined at different time points. The p.Y213H
mutant protein was slightly less stable that normal VRK1
(Fig. S3).
Effect of the VRK1(Y213H) mutant on the
formation of Cajal bodies
Phosphorylation of coilin regulates the assembly and sta-
bility of Cajal bodies.7,44 Therefore, we studied the possi-
ble effect of the Y213H mutant on the formation of Cajal
bodies. For this purpose, we used Hela cells in which the
endogenous human VRK1 was depleted by siRNA. These
human VRK1 depleted cells were transfected with the
murine VRK1, either wild-type (mVRK1) or containing
the Y213H mutant (mVRK1-Y213H). In transfected cells
depleted of human endogenous VRK1 there was a loss of
Cajal bodies, and this effect was rescued in cells express-
ing the murine wild-type VRK1, but not by the murine
VRK1-Y213H mutant protein (Fig. 4).
Discussion
The heterogeneity of the neuromotor syndromes associ-











Figure 2. Structural modeling of the human VRK1-Y213H variant protein. (A) Structure of the wild-type VRK1 activation loop after 200 nsec of
free molecular dynamics. Position of C-terminal tail interacting with the activation loop is indicated (magenta). The activation loop is colored in
green. Position of residues Tyr213, Tyr311 (blue, not in the activation loop), Lys211, Arg219 and Glu361 (grey, located in the C-terminal tail) is
indicated. (B) Structure of the activation loop of VRK1-Y213H variant after 200 nsec of free molecular dynamics. Note the displacement of the
loop compared to the wild-type structure and the different position of the mutated residue (His213). No interaction was detected between the
mutated activation loop and the C-terminal tail of VRK1.
Figure 3. Kinase activity of the wild-type VRK1 and mutant VRK1-Y213H using different phosphorylation substrates. (A) Phosphorylation of
histone H3 by wild-type VRK1 (WT), VRK1-T213H and kinase-dead VRK1-K179E in Thr3 detected with a phospho-specific antibody. (B)
Phosphorylation of histone H2AX in a radioactive kinase assay. (C) Phosphorylation of coilin in a radioactive kinase assay. (D) Phosphorylation of
p53 in a radioactive kinase assay. (E) Phosphorylation of 53BP1 in a radioactive kinase assay. One representative gel is shown, and the three
independent experiments are shown is Figure S2.
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contribution is likely to be mediated by downstream
direct targets. All pathogenic variants have in common
two possible effects. Some have a reduction of the mutant
protein stability, which leads to reduced protein levels.
Others have a reduction of their kinase activity with
respect to several of its known specific target proteins,34
some of which are already associated with neurological
development and diseases, such as proteins regulating
chromatin epigenetic changes, neural development or
response to cellular stress and DNA damage.
In this report, we have shown that the VRK1(Y213H)
mutant protein is unable to phosphorylate several of its
substrates including histone H3, H2AX, p53, 53BP1, and
coilin, all of them are pathogenically associated with heredi-
tary neurological/neuromotor syndromes. Functionally, this
impaired VRK1 kinase activity implicates a loss of func-
tions, which have to be linked to distal motor neuropathies
and SMA phenotype. The most likely intermediate step in
the pathogenesis VRK1(Y213H) is a consequence of the
inability of the Y213H mutant protein to phosphorylate
and regulate coilin, which can alter its associated proteins
and functions. Coilin is the scaffold protein of Cajal
Bodies45 discovered more than one hundred years ago,46
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Figure 4. Rescue of Cajal body formation by wild-type VRK1 and mutant VRK1-Y213H. Endogenous human VRK1 was depleted with si-VRK1-02
and cells were transfected with either murine VRK1 wild-type (muVRK1) or with the murine VRK1 Y213H variant (muVRK1-Y213H). (A) Images of
confocal microscopy showing the presence or absence of Cajal bodies assembled on coilin (red). (B) Quantification of the presence or absence of
Cajal bodies in cells that after depletion of endogenous human VRK1 were transfected with either wild-type of the Y213H mutant murine VRK1.
(C) Immunoblot to show the depletion of endogenous human VRK1 and its replacement by either murine VRK1 or the murine Y213H VRK1
mutant.
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function of Cajal bodies is not well understood, but it is a
ribonucleoprotein complex that participates in RNA pro-
cessing.47,48 In a murine coilin knockout models there is a
failure to recruit SMN1 to defective or absent CBs.49,50 All
human VRK1 mutant proteins, directly or indirectly fail to
form CBs7,34,51 and mimic the coilin knockout. Further-
more, SMN1 protects against mutant SOD1 toxicity.52
Mutations in SOD1 disrupt the recruitment of SMN1 to
Cajal bodies,53 and mutations in VCP (valosin) contribute
to development of ALS in KO mice,54 all these proteins
form complexes with VRK1 (unpublished).
Most of the known human VRK1 pathogenic variants
are unable to form CBs,34 as it also occurs with the
Y213H mutant. Moreover, in cells obtained from
patients with compound R219L/W254L mutations, there
are no CBs in motor neurons derived from human
induced pluripotent stem cells.51 In a murine model, the
human VRK1(R358X) mutant impairs cell cycle progres-
sion and migration of neuronal progenitors in early
embryogenesis.55 Moreover, VRK1 partial knockdown in
mice causes a motor dysfunction.56 Nuclear bodies, such
as CBs, are regulated during embryogenesis,57 and their
alteration is very likely to cause neurological disorders.
In this context, VRK1 regulates the assembly and disas-
sembly of CB mediated by a specific phosphorylation of
coilin that controls its stability and the formation of
complexes with other proteins.7 Thus, functionally defi-
cient VRK1 mutations alter the physiological dynamics
of CBs, and consequently of its associated proteins and
functions. This has been shown to be the case for
Y213H (this report) and for other mutants.34 The
heterogeneity of the VRK1 mutations suggests that there
might be differences in their specific protein interactions
that lead to some heterogeneity among the associated
neuromotor syndromes by altering the functionality of
Cajal bodies.
Another target of VRK1, p53, regulates WRAP53 that
is required for CB formation and maintenance of genome
integrity,58,59 but the activation of p53 by phosphoryla-
tion is impaired in the case of the VRK1(Y213H) mutant
protein. CBs are associated with ribonucleoproteins com-
plexes involved in RNA processing, but the consequences
of their alteration is unknown.47,60 In the CBs assembled
on coilin there are other proteins such as SMN1, associ-
ated with SMA,4 VCP associated with amyotrophic lateral
sclerosis (ALS),61 and ataxin 1 (ATXN1) associated with
ataxia.62 Alterations in any of them cause a distal neuro-
motor phenotype.
All the VRK1 mutants are either homozygous or com-
pound heterozygous. The heterogeneity of the neurologi-
cal phenotypes associated with VRK1 pathogenic variants
has some common features. All patients presented a
functional alteration of motor neuron function, mainly
as distal motor neuropathies, spinal muscular atrophy
(SMA) or amyotrophic lateral sclerosis (ELA). However,
they differed in their severity and age of presentation,
although initial symptoms started during infancy in most
cases and are progressive. There are also important dif-
ferences in intellectual ability ranging from normal to
very severe deficiency. Some additional neurological
symptoms are associated. This heterogeneity is unlikely
to be only the result of the specific VRK1 mutant, since
molecularly they have a similar defective function,34 but
rather by the contribution of additional variants in other
genes, which differ among patients. However, when more
than one case occurs within a family sharing the same
mutant, the phenotype is similar among the affected
family members.17
An alternative pathogenic mechanism implicating the
contribution of VRK1 may be a consequence of its inter-
action with GARS,41 a gene whose mutations are also
associated with distal neuropathies.63–65 However, the role
of aminoacyl-tRNA-synthetases in these diseases is
unknown, but may be a consequence of altering neurite
formation66 and peripheral axons.67,68
We conclude that VRK1 mutations, associated with dis-
tal neuromotor syndromes of unknown origin, should be
considered as a rare underlying pathogenic mechanism.
Since defective CBs assembly and associated functions are
common to a group of heterogeneous distal neuromotor
syndromes, whose final neurological phenotype will be
determined by the genetic background of the affected
individual. Distal motor neuropathies are a consequence
of a mutation in any of the different components of
nuclear suborganelles, such as CBs, and which lead to this
group of related neurological phenotypes.
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Figure S1. Structural modeling of VRK1 Y213H variant.
(A) 3D structure of wild-type VRK1 protein (PDB id:
2LAV). The activation loop is colored in green. Position
of residues Tyr213, Tyr311 (blue, not in the activation
loop), Lys211, Arg219 and Glu361 (grey, located in the
C-terminal tail) are indicated.
Figure S2. Phosphorylation of several substrates by VRK1
and VRK1-Y213H in triplicate. (A) Histone H3. (B) His-
tone H2AX. (C) Coilin. (D) TP53. (E) 53BP1.
Figure S3. Protein stability of the wild-type VRK1 and
mutant VRK1-Y213H proteins.
Table S1. List of primary and secondary antibodies used
in this work.
Data S1. This refers to databases correctly placed before
in the text.
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